Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Oropharyngeal Cancer.

Inclusion Criteria: * Squamous cell cancer of oropharynx, p 16 positive * American Joint Commission on Cancer version-7 (AJCC-7) Stage III (T1N1, T2N1, T3N0, T3N1) and stage IVa (T1N2, T2N2, T3N2) * Treatment Naive * No evidence of distant metastatic disease * Fit for surgery, and primary tumor assessed surgically resectable with negative margins via transoral approach * Age \> 18 years * Karnofsky performance status \> 60% or Eastern Cooperative Oncology Group (ECOG) \< 2 * Absolute neutrophil count (ANC) \> 2,000, platelets \> 100,000 and calculated creatinine clearance \> 50 cc/min * Signed study specific consent form * No other malignancies except cutaneous basal cell carcinoma (BCC) or squamous cell carcinoma (SCC) within the last 5 years * Agree to use effective contraception while on the study. Women of child bearing potential must have a negative pregnancy test, and not be lactating. Exclusion Criteria: * Patients with advanced T4 cancer unresectable without organ preservation * P16 negative tumor * N3 disease (Stage IVB AJCC-7) * 5 or more positive cervical lymph nodes at presentation * Distant metastatic disease (Stage IVC) * Radiological evidence of gross extracapsular nodal tumor invasion * Anatomy not allowing transoral access and exposure * Prior head and neck cancer at any time (Other than BCC or SCC of skin) * Coexistent second malignancy or history within 5 years of prior malignancy (other than BCC or early SCC skin or curatively treated Stage I carcinoma of cervix) * Peripheral neuropathy \>/= grade 1 * Have had prior Taxanes or Cisplatin * Concurrent infection * Coexisting medical illness of a severity that might interfere with treatment or follow-up, or who do not have the ability to give informed consent. * Receiving any other investigational agent while on the study